Tarceva (Non-Small Cell Lung Cancer) – Forecast and Market Analysis to 2022: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on sales@marketoptimizer.org with Tarceva (Non-Small Cell Lung Cancer) – Forecast and Market Analysis to 2022 in subject line and your contact details. Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets. Roche/Genentech’s Tarceva is an EGFR TKI delivered as a daily oral tablet. It is approved by the FDA for use as a maintenance monotherapy and in second-line treatment after failure of at least one prior chemotherapy regimen for all patients, regardless of EGFR mutation status. In May 2013, the US FDA approved Tarceva’s label extension into the first-line therapy of EGFR-mutant patients, along with an EGFR companion diagnostic developed by Roche Diagnostics.
Complete report available at http://www.marketoptimizer.org/tarceva-non-small-cell-lung-cancerforecast-and-market-analysis-to-2022.html . Scope - Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Tarceva including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Tarceva for the top nine countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for NSCLC - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Tarceva performance - Obtain sales forecast for Tarceva from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China) Inquire for discount @ http://www.marketoptimizer.org/contacts/discount?rname=2424 . (Report price: Single user license- US$ 3495 ) Table of Contents 1 Table of Contents 5 1.1 List of Tables 7 2 Introduction 8 2.1 Catalyst 8 2.2 Related Reports 9 2.3 Upcoming Related Reports 11 3 Disease Overview 12 3.1 Etiology and Pathophysiology 12 3.1.1 Etiology 12 3.1.2 Pathophysiology and Histology 12 3.1.3 NSCLC Biomarkers 13 3.1.4 Quality of Life 14 3.2 Symptoms 15 4 Disease Management 17
Buy a Copy of the Report @ http://www.marketoptimizer.org/contacts/purchase?rname=2424 . Table of Contents 4.1 Treatment Overview 17 4.1.1 Diagnosis 19 4.1.2 Clinical Staging 19 4.1.3 Screening and Early Detection 22 4.1.4 Localized Procedures and Therapies 23
4.1.5 Systemic Chemotherapy 24 4.1.6 Targeted Therapy 25 5 Competitive Assessment 28 5.1 Overview 28 5.2 Strategic Competitor Assessment 29 6 Tarceva (erlotinib hydrochloride) 32 6.1 Overview 32 6.2 Efficacy 33 6.3 Safety 36 6.4 SWOT Analysis 36 Contact sales@marketoptimizer.org / Call +1 888 391 5441 for further information on “Tarceva (NonSmall Cell Lung Cancer) – Forecast and Market Analysis to 2022” report OR for any other market research and intelligence needs you may have for your business.